Integrated Biopharma Financials
INBPDelisted Stock | USD 0.23 0.01 4.55% |
With this module, you can analyze Integrated financials for your investing period. You should be able to track the changes in Integrated Biopharma individual financial statements over time to develop the understanding of its risk, liquidity, profitability, or other critical and vital indicators.
Integrated |
Understanding current and past Integrated Biopharma Financials, including the trends in assets, liabilities, equity and income are directly related to making proper and timely investing decisions. All of Integrated Biopharma's financial statements are interrelated, with each one affecting the others. For example, an increase in Integrated Biopharma's assets may result in an increase in income on the income statement.
The data published in Integrated Biopharma's official financial statements usually reflect Integrated Biopharma's business processes, product offerings, services, and other fundamental events. But there are other numbers, ratios, or fundamental indicators derived from these statements that are easier to understand and visualize within the underlying realities that drive quantitative information of Integrated Biopharma. For example, before you start analyzing numbers published by Integrated accountants, it's critical to develop an understanding of what Integrated Biopharma's liquidity, profitability, and earnings quality are in the context of the Personal Products space in which it operates.
Please note, the presentation of Integrated Biopharma's financial position, as portrayed in its financial statements, is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, Integrated Biopharma's management is honest, while the outside auditors are strict and uncompromising. Whatever the case, the imprecision that can be found in Integrated Biopharma's accounting process means that the reasonable investor should take a skeptical approach toward the financial statement analysis of Integrated Biopharma. Please utilize our Beneish M Score to check the likelihood of Integrated Biopharma's management manipulating its earnings.
Integrated Biopharma Stock Summary
Integrated Biopharma competes with Premier Foods, Aryzta AG, Calbee, Toyo Suisan, and Treehouse Foods. Integrated BioPharma, Inc., together with its subsidiaries, manufactures, distributes, markets, and sells vitamins, nutritional supplements, and herbal products primarily in the United States and Luxembourg. Integrated BioPharma, Inc. was incorporated in 1980 and is based in Hillside, New Jersey. Integrated Biopharma operates under Packaged Foods classification in the United States and is traded on OTC Exchange. It employs 147 people.Specialization | Consumer Defensive, Packaged Foods |
Instrument | USA OTC Stock View All |
Exchange | OTCQX Exchange |
ISIN | US45811V1052 |
CUSIP | 45811V105 163527203 45818E106 |
Location | New Jersey; U.S.A |
Business Address | Building 15, Hillside, |
Sector | Personal Products |
Industry | Consumer Staples |
Benchmark | NYSE Composite |
Website | www.ibiopharma.com |
Phone | 888 319 6962 |
Currency | USD - US Dollar |
You should never invest in Integrated Biopharma without having analyzed its financial statements. Do not rely on someone else's analysis or guesses about the future performance of Integrated OTC Stock, because this is throwing your money away. Analyzing the key information contained in Integrated Biopharma's financial statements can give you an edge over other investors and help to ensure that your investments perform well for you.
Integrated Biopharma Key Financial Ratios
Generally speaking, Integrated Biopharma's financial ratios allow both analysts and investors to convert raw data from Integrated Biopharma's financial statements into concise, actionable information that can be used to evaluate the performance of Integrated Biopharma over time and compare it to other companies across industries. There are many critical financial ratios that investors are exposed to on a daily basis, but they are usually grouped into few meaningful categories from each financial statement that Integrated Biopharma reports annually and quarterly.Integrated Financial Ratios Relationships
Comparative valuation techniques use various fundamental indicators to help in determining Integrated Biopharma's current stock value. Our valuation model uses many indicators to compare Integrated Biopharma value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Integrated Biopharma competition to find correlations between indicators driving Integrated Biopharma's intrinsic value. More Info.Integrated Biopharma is currently regarded as number one stock in return on equity category among related companies. It is currently regarded as number one stock in return on asset category among related companies reporting about 0.26 of Return On Asset per Return On Equity. The ratio of Return On Equity to Return On Asset for Integrated Biopharma is roughly 3.77 . Comparative valuation analysis is a catch-all model that can be used if you cannot value Integrated Biopharma by discounting back its dividends or cash flows. This model doesn't attempt to find an intrinsic value for Integrated Biopharma's OTC Stock. Still, instead, it compares the stock's price multiples to a benchmark or nearest competition to determine if the stock is relatively undervalued or overvalued. The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the Integrated Biopharma's earnings, one of the primary drivers of an investment's value.Integrated Biopharma Market Pulse
Quote | 0.23 |
Change(%) | 4.55 |
Change | 0.01 |
Open | 0.22 |
Low | 0.22 |
High | 0.23 |
Volume | 0 |
Exchange | OTCQX |
About Integrated Biopharma Financials
What exactly are Integrated Biopharma Financials? Typically, a company's financial statements are the reports that show the financial position of the company. Three primary documents fall into the category of financial statements. These documents include Integrated Biopharma's income statement, its balance sheet, and the statement of cash flows. Potential Integrated Biopharma investors and stakeholders use financial statements to determine how well the company is positioned to perform in the future. Although Integrated Biopharma investors may use each financial statement separately, they are all related. The changes in Integrated Biopharma's assets and liabilities, for example, are also reflected in the revenues and expenses that we see on Integrated Biopharma's income statement, which results in the company's gains or losses. Cash flows can provide more information regarding cash listed on a balance sheet, but not equivalent to net income shown on the income statement. Please read more on our technical analysis and fundamental analysis pages.Steps to analyze Integrated Biopharma Financials for Investing
There are several different ways that investors can use financial statements to try and predict whether a stock price will go up or down. Unfortunately, there is no surefire formula, but there are some general guidelines you should consider when looking at the numbers. First, realize what kind of company it is so you know if its revenues are more likely to grow or shrink over time. For example, a software company's revenue is expected to increase yearly due to new products and services that its customers will want to buy. At the same time, a car manufacturer might not be able to sell as many cars when the economy slows down, so it would have less net income during those times. Second, pay attention to its debt-to-equity ratio because this number will tell you how much risk it has. If a company such as Integrated Biopharma is not taking on any additional risks, its debt-to-equity should be less than one. As a general rule of thumb, if the market value or book value (which can be found in the footnotes) of assets exceeds the company's liabilities, then it is probably in good shape. Finally, use other financial statements to determine if a stock price will go up or down because investors are always looking for growth opportunities when they buy new stocks. For example, if you see that the net revenue of Integrated has grown by more than 25% over the last five years, then there is a good chance that it will continue growing by at least 20% or more each year. On the other hand, if you see that net revenue has only increased by about 15%, which is barely above inflation levels, then chances are it will not grow much faster than this over time, and investors may shy away from buying it. In summary, you can determine if Integrated Biopharma's financials are consistent with your investment objective using the following steps:- Review Integrated Biopharma's balance sheet accounts, such as liabilities and equity, to understand its overall financial position.
- Analyze the income statement and examine the company's revenue, expenses, and profits over time to determine its financial performance.
- Study the cash flow inflows and outflows to understand Integrated Biopharma's liquidity and solvency.
- Look at the growth rates in revenue, earnings, and cash flow over time to determine its potential for future growth.
- Compare Integrated Biopharma's financials to those of its peers to see how it stacks up and identify any potential red flags.
- Use valuation ratios to evaluate the company's financials using commonly used ratios such as the price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and enterprise value-to-earnings before interest, taxes, depreciation, and amortization (EV/EBITDA) ratio to determine if Integrated Biopharma's stock is overvalued or undervalued.
Integrated Biopharma Thematic Clasifications
Integrated Biopharma is part of several thematic ideas from Processed Foods to Natural Foods. If you are a theme-oriented, socially responsible, and at the same time, a result-driven investor, you can align your investing habits with your values without jeopardizing your expectations about returns. You can easily create an optimal portfolio of stocks, ETFs, funds, or cryptocurrencies based on a specific theme of your liking. Get More Thematic IdeasIntegrated Biopharma April 18, 2024 Opportunity Range
Along with financial statement analysis, the daily predictive indicators of Integrated Biopharma help investors to analyze its daily demand and supply, volume, patterns, and price swings to determine the real value of Integrated Biopharma. We use our internally-developed statistical techniques to arrive at the intrinsic value of Integrated Biopharma based on widely used predictive technical indicators. In general, we focus on analyzing Integrated OTC Stock price patterns and their correlations with different microeconomic environment and drivers. We also apply predictive analytics to build Integrated Biopharma's daily price indicators and compare them against related drivers.
Information Ratio | (0.03) | |||
Maximum Drawdown | 24.7 | |||
Value At Risk | (9.09) | |||
Potential Upside | 8.7 |
Check out Risk vs Return Analysis to better understand how to build diversified portfolios. Also, note that the market value of any otc stock could be tightly coupled with the direction of predictive economic indicators such as signals in bureau of labor statistics. Note that the Integrated Biopharma information on this page should be used as a complementary analysis to other Integrated Biopharma's statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Equity Forecasting module to use basic forecasting models to generate price predictions and determine price momentum.
Other Consideration for investing in Integrated OTC Stock
If you are still planning to invest in Integrated Biopharma check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Integrated Biopharma's history and understand the potential risks before investing.
Equity Analysis Research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities | |
Stock Tickers Use high-impact, comprehensive, and customizable stock tickers that can be easily integrated to any websites | |
Cryptocurrency Center Build and monitor diversified portfolio of extremely risky digital assets and cryptocurrency | |
Portfolio File Import Quickly import all of your third-party portfolios from your local drive in csv format | |
Watchlist Optimization Optimize watchlists to build efficient portfolios or rebalance existing positions based on the mean-variance optimization algorithm | |
Risk-Return Analysis View associations between returns expected from investment and the risk you assume | |
Portfolio Center All portfolio management and optimization tools to improve performance of your portfolios | |
Money Flow Index Determine momentum by analyzing Money Flow Index and other technical indicators | |
Investing Opportunities Build portfolios using our predefined set of ideas and optimize them against your investing preferences | |
Sectors List of equity sectors categorizing publicly traded companies based on their primary business activities | |
Efficient Frontier Plot and analyze your portfolio and positions against risk-return landscape of the market. | |
Piotroski F Score Get Piotroski F Score based on the binary analysis strategy of nine different fundamentals | |
CEOs Directory Screen CEOs from public companies around the world |